Rocket Lab USA's stock experienced a sharp intraday pullback, falling -10.7% in morning trading as investor enthusiasm tied to the SpaceX IPO narrative unwound and triggered aggressive profit-taking. The decline pulled the share price back from levels close to its all-time high, extending a reversal that began after a previous session's surge.
That earlier spike on the prior session was linked to news that SpaceX had accelerated its timeline for going public. The calendar showed a marketing roadshow set for June 4, pricing slated for June 11, and trading expected to begin on June 12. The announcement briefly lifted sentiment across space-related equities and helped send Rocket Lab's shares higher; the stock had jumped nearly 11% at the open on May 18 before giving back most of those gains, and the latest session continued that selloff.
Valuation dynamics under the microscope
At roughly a $72 billion market capitalization and about $200 million in quarterly revenue, Rocket Lab is trading at about 90 times annualized sales. That multiple assumes significant operational success for the company's Neutron rocket program - specifically that Neutron will launch, scale and effectively compete with SpaceX's Falcon 9. If Neutron does not meet those milestones, the generous sales multiple is unlikely to be justified.
Wall Street commentary has underscored the valuation tension. Goldman Sachs analyst Noah Poponak kept a Neutral rating on the stock while raising his price target to $76, citing persistent risks associated with Rocket Lab's expansion plans and the execution demands of the Neutron program.
Volatility and market context
Despite a large market capitalization by some measures, Rocket Lab's shares behave like a higher-risk, smaller-cap name. The stock's beta is well above 2 relative to the S&P 500, which means broad market declines can be amplified in RKLB's price action; the article notes that a 10% market drawdown can translate into a 25%–40% move in RKLB on any Neutron-related headline. That sensitivity was evident as broader indices weakened: the NASDAQ declined -1.1%, the S&P 500 fell -0.7% and the Dow slipped -0.3% during the session.
Technical indicators also signaled stress. A pivot top point on May 14 generated a technical sell signal, and further downside was indicated until a new bottom pivot is established, according to the coverage in the session.
Execution risks: Neutron's slipping timeline
Neutron, the cornerstone of Rocket Lab's longer-term bull case, has seen its expected debut repeatedly delayed. The timeline moved from 2024 to 2025 and is now pushed into 2026, with a propellant tank failure during testing cited as the proximate cause of the most recent delay. That failure has shifted the earliest likely debut to the fourth quarter of 2026, highlighting the substantial execution risk investors are pricing into the stock at current levels.
The combination of a rapid run-up of more than 60% in recent weeks, elevated valuation multiples, a high-beta trading profile, and the fading space-sector excitement tied to a potential SpaceX listing all converged to drive today's steep retreat in RKLB shares.
Where things stand
Investors appear to be transitioning from celebrating the potential of a broader space-sector uplift from a public SpaceX to scrutinizing the competitive implications of a listed SpaceX operating in public markets. That shift in focus, coupled with the mechanical realities of Neutron's delays and a technical sell signal, produced a notable re-pricing of Rocket Lab shares during the session.
Given the factors at play - valuation stretched relative to current revenue, concentrated execution risk around Neutron, and elevated sensitivity to market moves - further volatility should be expected until clearer operational milestones are achieved or a new technical bottom is established.